相关临床试验
94
26 进行中
药物批准
43
批准总数
监管机构
3
监管机构数
成立时间
N/A
进行中（未招募）
25
26.6%
已完成
59
62.8%
尚未招募
1
1.1%
招募中
8
8.5%
终止
1
1.1%
- Eloxx Pharmaceuticals completed a $66.0 million public offering and uplisted to Nasdaq, ending Q2 2026 with $62.0 million in cash and no outstanding debt. - The company plans to initiate a Phase 2b trial of exaluren in nonsense mutation Alport syndrome in Q3 2026, with topline data expected by mid-2027. - The European Commission granted orphan medicinal product designation for exaluren in autosomal dominant polycystic kidney disease (ADPKD) in July 2026. - Cash runway is expected to fund operations through data readouts for both Alport syndrome and ADPKD, extending into mid-2028.
- Almirall and Shenzhen CrystalO Biopharma announced a collaboration to discover and develop novel small-molecule drugs targeting ion channels for skin diseases. - CrystalO will leverage its AI- and structure-based drug discovery platform to advance candidates through proof-of-concept clinical testing, while Almirall leads global development and commercialization outside mainland China. - CrystalO receives an upfront payment and is eligible for milestone payments and tiered royalties on global sales, with reciprocal royalties to Almirall on sales in mainland China. - The deal expands Almirall's innovation footprint in China and reinforces its R&D pipeline in medical dermatology, building on over €1 billion invested in the field over the past decade.
- The global AI in antibody discovery market was valued at USD 546.17 million in 2025 and is projected to reach USD 3,162.19 million by 2034, expanding at a CAGR of 21.57%. - North America dominated the market with a 43.72% share in 2025, while the Asia Pacific region is expected to grow at the fastest rate with a CAGR of 23.26%. - Monoclonal antibodies accounted for the largest antibody modality share at 54.41%, driven by established clinical pathways and abundant training datasets for AI model development. - Structure prediction technology led the market with a 32.12% share in 2025, while generative AI and protein language models are forecast to grow at a CAGR of 22.33%.
- Almirall has nominated LAD116, an intratumoral mRNA/LNP therapy developed in collaboration with etherna, for IND-enabling studies targeting non-melanoma skin cancer. - The therapy is designed to generate a potent immune response directly within the tumor microenvironment using etherna's proprietary mRNA and lipid nanoparticle platform technology. - The collaboration will now focus on manufacturing GMP-grade material for IND-enabling studies and intended Phase I clinical trials. - This advancement represents a significant milestone in applying mRNA technology to dermatological oncology, addressing unmet medical needs in non-melanoma skin cancer treatment.
- China's National Medical Products Administration has approved Seysara (sarecycline hydrochloride), the first oral antibiotic specifically developed for dermatological use, for treating moderate-to-severe acne vulgaris in patients aged 9 and older. - Sarecycline is a narrow-spectrum tetracycline-class antibiotic with unique dual binding to the 70S ribosome, which reduces the likelihood of Cutibacterium acnes developing antimicrobial resistance. - Almirall has partnered with Sinomune for commercialization and distribution in China, with the product expected to become available to physicians and patients in 2026. - The approval expands access to an innovative acne treatment that has demonstrated consistent efficacy and favorable safety profile in clinical studies conducted in both the United States and China.
- Almirall announces the LumiNE Phase III clinical trial to evaluate lebrikizumab's efficacy in treating nummular eczema, a debilitating chronic skin condition distinct from atopic dermatitis. - The study will enroll at least 270 patients across 60 European centers for up to 48 weeks, targeting the IL-13 cytokine pathway that plays a central role in nummular eczema pathogenesis. - Nummular eczema affects 0.1% to 9% of the population with coin-shaped, itchy patches that significantly impair quality of life and are often difficult to manage with standard topical therapies. - The trial represents Almirall's lifecycle management strategy to expand lebrikizumab's approved indication beyond moderate-to-severe atopic dermatitis to address high unmet medical needs in dermatology.
- Simcere Pharmaceutical Group announced that SIM0278, a regulatory T cell-preferential IL-2 mutant fusion protein, has entered Phase II clinical trials in China for moderate-to-severe atopic dermatitis treatment. - The randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration of SIM0278. - SIM0278's unique mechanism selectively activates regulatory T cells while maintaining low affinity for effector T cells, potentially restoring immune balance without affecting other immune cell populations. - The drug demonstrated good tolerability, appropriate pharmacokinetic properties, and preliminary efficacy in completed Phase I studies, positioning it as a potential best-in-class treatment for immune disorders.
- The POSITIVE trial demonstrates that tildrakizumab significantly improves psychological wellbeing in psoriatic disease patients, with WHO-5 scores increasing from 53.7 at baseline to 70.43 at two years, surpassing European population norms. - Clinical outcomes showed sustained improvement with mean PASI scores decreasing from 12.9 at baseline to 1.3 at week 104, with 79.0% of patients maintaining PASI ≤2 at two years. - The study revealed that 29.5% of patients experienced "psycholag," a delay in psychological recovery despite rapid skin clearance, highlighting the complex relationship between physical and mental health outcomes. - Quality of life measures and family burden scores showed consistent improvement throughout the 24-month observation period, with favorable safety outcomes reported in 11.1% of patients experiencing treatment-related adverse events.
- Almirall and Absci have expanded their AI drug discovery collaboration to include a second dermatology target following successful delivery of AI-designed antibody leads against a difficult-to-drug target. - The collaboration combines Absci's Integrated Drug Creation™ platform with Almirall's dermatology expertise to develop novel therapeutics for chronic and debilitating skin diseases. - Under the expanded partnership terms, Absci is eligible to receive up to approximately $650 million in milestone payments across both programs, plus royalties on potential product sales. - The partnership demonstrates the potential of AI de novo drug design to unlock novel biology where traditional drug discovery approaches have previously failed.
- AMD has invested $20 million in Absci and formed a partnership to power AI-driven drug discovery platforms, marking the chipmaker's strategic entry into pharmaceutical research and development. - Absci's Integrated Drug Creation platform, which can screen billions of cells weekly and produce lab-validated candidates in six weeks, will utilize AMD's high-performance computing solutions for complex biological modeling. - The partnership follows AMD's rival NVIDIA's established presence in AI drug discovery, with Absci already maintaining successful collaborations with major pharmaceutical companies including AstraZeneca, MSD, and Almirall.
